First some background,...for the wino's (gggggg)
Polyphenols are a group of naturally abundant chemical compounds which are present in many flowers,
barks, and berries. One well known polyphenol is resveratrol, a compound found in grapes and red wine.
Scientists have long researched the suspected benefit of resveratrol in the treatment of various conditions
such as cardiovascular disease, cancer, and aging. Resverlogix is currently engaged in researching the role
of resveratrol and other polyphenols in the expression of Apolipoprotein A1 (Apo A1) which is a major
component of HDL (the “good cholesterol”).
In a program related to the companies Company’s polyphenol research, Resverlogix has developed a novel
derivative of resveratrol which has the potential to be one of the first drugs to provide simultaneous
antioxidant and vasodilation activity in addition its capability to induce reverse cholesterol transport
through the increased expression of Apo A1. The successful development of this drug could represent a
groundbreaking new chapter in the treatment of cardiovascular disease.
Now the press release,...
NOVEMBER 18, 2003 - 15:48 ET
A Journal of American Medical Association Article
Delivers Good News for Resverlogix's Main Field of
Technology Development.
CALGARY ALBERTA--Resverlogix Corp. (TSX-V:RVX) announced that an
article titled "Effect of Recombinant Apo A-1 Milano on Coronary
Atherosclerosis in Patients With Acute Coronary Syndromes" in the
November 5th edition of the Journal of the American Medical
Association (J.A.M.A.) significantly validates reverse
cholesterol transport (RCT) as a now proven method of removing
atherosclerotic plaques from the body. The new data relating to
the actions of RCT further underscores the importance of
augmenting this normal physiological process in reversing
cardiovascular disease. The article relates to the use of a
particular recombinant Apo A1 Milano program to reduce the fatty
arterial plaques, which cause heart attacks, by 10 times more
than the statins that are currently used in almost all
cholesterol drugs currently on the market. The expression of
Apolipoprotein A1 is at the center of the technology currently
being deployed by Resverlogix. It should be noted that the study
was in no way supported or funded by Resverlogix and in no way
relates to Resverlogix outside of proving the viability of
Company's field of research.
Resverlogix's primary technology involves the mechanism of
regulating Apo A1 and its effect on HDL, the "good cholesterol".
J.A.M.A.'s exciting new study has now proven that Apo A1 Milano
expressing HDL cholesterol has the ability to rapidly facilitate
reverse cholesterol transport, a natural process in which
cholesterol is removed from the body's arteries via the liver.
The research was led by Steven E. Nissen, M.D., F.A.C.C., Medical
Director of the Cleveland Clinic Cardiovascular Coordinating
Center. Resverlogix's enthusiasm about the potential effects of
this research are echoed by Dr. Daniel Rader, a University of
Pennsylvania Cardiologist who wrote an accompanying editorial in
J.A.M.A., where he stated "it's very exciting for the field. It
is something that no one expected."
"This is a very exciting time to be involved in the field of HDL
research," says Mr. Don McCaffrey, President and CEO of
Resverlogix. "One way to explain the current situation of
Resverlogix is imaging a pre-clinical development company in the
early 90's with the ability to identify statins and determine how
well they may work, 10 years before they became the billion
dollar industry they are today. Our current assay technology and
work being carried out in our Calgary lab facilities are doing
just that in relation to Apo A1, HDL and reverse cholesterol
transport."
For a number of years the cholesterol therapy market has centered
around statin drugs that reduce LDL, the "bad cholesterol". While
statin drugs remain the highest selling category of
pharmaceutical worldwide, they are only able to slow, or minutely
reverse, the formation of dangerous atherosclerotic plaques as
they lack HDL's ability to remove these plaques drastically.
Successful development of Apo A1 and HDL technology will create
new lines of drugs with the potential to equal or surpass statin
drugs in both sales and efficiency.
This recent development in the cardiovascular drug industry,
which shows for the first time that it may be possible to rapidly
reverse the main underlying cause of heart attacks, has been well
received by the market. The stock prices of other publicly traded
companies engaged in HDL research have increased an average of
42% since J.A.M.A.'s announcement.
About Resverlogix Corp.
Resverlogix Corp. is a biotechnology research and development
company dedicated to commercialization of innovative therapies.
Resverlogix's first research announcement involved the management
of cholesterol through the expression of "Apo A1", an important
factor in reverse cholesterol transport. In addition, the Company
has also acquired a cell therapy for cancer involving a TGF-beta
inhibiting protein. The Company has adopted a conservative
strategy of only developing technology to the beginning of human
clinical trials at which point licensing partners will be
pursued. Resverlogix Corp. trades on the TSX Venture Exchange
under the symbol RVX. For further information, please visit our
web site at: www.resverlogix.com. |
